We are live on ! Find out more
GS

Gilead Sciences Portfolio holdings

AUM $2.12B
1-Year Est. Return 143.53%
This Fund
S&P 500
This Quarter Est. Return
+21.54%
1 Year Est. Return
+143.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.12B
AUM Growth
+$182M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
–
Closed
–

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$772M 36.44%
6,720,803
– –
RCUS icon
2
Arcus Biosciences
RCUS
$3.55B
$679M 32.05%
31,424,760
– –
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$501M 23.67%
16,707,477
– –
ASMB icon
4
Assembly Biosciences
ASMB
$498M
$125M 5.9%
4,505,391
– –
KYTX icon
5
Kyverna Therapeutics
KYTX
$444M
$35.6M 1.68%
4,126,119
– –
XLO icon
6
Xilio Therapeutics
XLO
$59.9M
$5.47M 0.26%
650,389
– –

Similar funds

BCM
Basswood Capital Management New York $2.12B AUM 19.53% 1-Year Est. Return
IVAV
Index Venture Associates VI St. Helier, Channel Islands, Jersey $2.11B AUM 13.76% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
HJGA
Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return
CF
Centaurus Financial Anaheim, California $2.1B AUM 21.28% 1-Year Est. Return
BWC
Blue Whale Capital London, United Kingdom $2.1B AUM 97.03% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Gilead Sciences's Q1 2026 Portfolio in Review

As of Q1 2026, Gilead Sciences held 6 positions worth $2.12B, up 9.4% from $1.94B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2026: portfolio turnover was 0%. Gilead Sciences opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Gilead Sciences's ten largest holdings make up 100% of its $2.12B portfolio in Q1 2026.
  • Gilead Sciences opened 0 new positions and closed 0 in Q1 2026.
  • Gilead Sciences's portfolio value rose 9.4% quarter-over-quarter to $2.12B.

Based on Gilead Sciences's 13F filing for Q1 2026, filed 8 May 2026.